Concise review: Workshop review: Understanding and assessing the risks of stem cell-based therapies

Stem Cells Translational Medicine

Volumn 4, Issue 4, 2015, Pages 389-400

  Heslop, James A ^a   Hammond, Thomas G ^a   Santeramo, Ilaria ^b   Piella, Agnés Tort ^a   Hopp, Isabel ^b   Zhou, Jing ^b   Baty, Roua ^b   Graziano, Enrique I ^c   Marco, Bernabè Proto ^c   Caron, Alexis ^d   Sköld, Patrik ^e   Andrews, Peter W ^f   Baxter, Melissa A ^g   Hay, David C ^h   Hamdam, Junnat ⁱ   Sharpe, Michaela E ^j   Patel, Sara ^k   Jones, David R ^l   Reinhardt, Jens ^m   Danen, Erik H J ⁿ   Ben David, Uri ^o   Stacey, Glyn ^p   Björquist, Petter ^q   Piner, Jacqueline ^r   Mills, John ^s   Rowe, Cliff ^t   Pellegrini, Giovanni ^u   Sethu, Swaminathan ^v   Antoine, Daniel J ^a   Cross, Michael J ^a   Murray, Patricia ^b   Williams, Dominic P ^s   Kitteringham, Neil R ^a   Goldring, Chris E P ^a,w   Kevin Park, B ^a   more..

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c Laboratorios Almirall ^*  (Spain)

^d SANOFIResearchand Development Disposition Safetyand Animal Research   (France)

^e UPPSALA UNIVERSITY   (Sweden)

^f UNIVERSITY OF SHEFFIELD   (United Kingdom)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

^h UNIVERSITY OF EDINBURGH   (United Kingdom)

ⁱ HEINRICH HEINE UNIVERSITY   (Germany)

^j OakMore Solutions Ltd   (United Kingdom)

^k RENEURON LTD   (United Kingdom)

^l MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^m PAUL EHRLICH INSTITUT   (Germany)

ⁿ LEIDEN UNIVERSITY   (Netherlands)

^o HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^p NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^q Arvid Wallgrens Backe 20   (Sweden)

^r GLAXOSMITHKLINE   (United Kingdom)

^s ASTRAZENECA   (United Kingdom)

^t Centre for Innovation and Enterprise   (United Kingdom)

^u UNIVERSITY OF ZURICH   (Switzerland)

^v VIT UNIVERSITY   (India)

^w Innovative Medicines Initiative SafeSciMET   (Belgium)

more..

Author keywords

Adult stem cells; Autologous stem cell transplantation; Cellular therapy; In vivo tracking; Pluripotent stem cells; Stem cell; Stem cell expansion; Stem cell transplantation

Indexed keywords

CD45 ANTIGEN;

ADULT STEM CELL; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CARCINOGENESIS; CELL CULTURE; CELL LABELING; CELL MIGRATION; CELL TRACKING; CELLULAR DISTRIBUTION; EMBRYONIC STEM CELL; FLOW CYTOMETRY; HUMAN; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MESENCHYMAL STEM CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLURIPOTENT STEM CELL; POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR; SAFETY; SCIENTIST; SPINE INJURY; STEM CELL EXPANSION; STEM CELL TRANSPLANTATION; THERAPY EFFECT; WORKSHOP; ADVERSE EFFECTS; AUTOTRANSPLANTATION; BIOLOGICAL THERAPY; CYTOLOGY; PROCEDURES; STEM CELL; TRANSPLANTATION;

CELL- AND TISSUE-BASED THERAPY; HUMANS; PLURIPOTENT STEM CELLS; STEM CELL TRANSPLANTATION; STEM CELLS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84930477917     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2014-0110     Document Type: Article

References (176)

1. Thomson JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell lines derived from human blastocysts. Science 1998;282:1145–1147.
2. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663–676.
3. Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells fromadult human fibroblasts by defined factors. Cell 2007;131:861–872.
4. Sarugaser R, Hanoun L, Keating A et al. Human mesenchymal stem cells self-renew and differentiate according to a deterministic hierarchy. PLoS One 2009;4:e6498.
5. Huber TL. Dissecting hematopoietic differentiation using the embryonic stem cell differentiation model. Int J Dev Biol 2010; 54:991–1002.
6. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006;354: 1813–1826.
7. Chao NJ, Emerson SG, Weinberg KI. Stem cell transplantation (cord blood transplants). Hematology Am Soc Hematol Educ Program 2004:354–371.
8. Gallico GG 3rd., O’Connor NE, Compton CC et al. Permanent coverage of large burn wounds with autologous cultured human epithelium. N Engl J Med 1984;311:448–451.
9. Zheng G-P, Ge M-H, Shu Q et al. Mesenchymal stem cells in the treatment of pediatric diseases. World J Pediatr 2013;9:197–211.
10. Cyranoski D. Next-generation stem cells cleared for human trial. Nature 2014. Available at http://www.nature.com/news/next-generationstem- cells-cleared-for-human-trial-1.15897. Accessed February 13, 2015
11. Schwartz SD, Hubschman JP, Heilwell G et al. Embryonic stem cell trials for macular degeneration: A preliminary report. Lancet 2012; 379:713–720.
12. Streilein JW. Ocular immune privilege: Therapeutic opportunities from an experiment of nature. Nat Rev Immunol 2003;3:879–889.
13. Amariglio N, Hirshberg A, Scheithauer BW et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 2009;6: e1000029.
14. Dlouhy BJ, Awe O, Rao RC et al. Autograft-derived spinal cord mass following olfactory mucosal cell transplantationin a spinal cord injury patient: Case report. J Neurosurg Spine 2014;21:618–622.
15. Tabakow P, Raisman G, Fortuna W et al. Functional regeneration of supraspinal connections in a patient with transected spinal cord following transplantation of bulbar olfactory ensheathing cells with peripheral nerve bridging. Cell Transplant 2014;23:1631–1655.
16. Andrews PW, Matin MM, Bahrami AR et al. Embryonic stem(ES) cells and embryonal carcinoma (EC) cells: Opposite sides of the same coin. Biochem Soc Trans 2005;33: 1526–1530.
17. Payne CM, Samuel K, Pryde A et al. Persistence of functional hepatocyte-like cells in immune-compromised mice. Liver Int 2011; 31:254–262.
18. Fujikawa T, Oh S-H, Pi L et al. Teratoma formation leads to failure of treatment for ´type I diabetes using embryonic stem cell-derived insulin-producing cells. Am J Pathol 2005;166: 1781–1791.
19. Ben-David U, Gan QF, Golan-Lev T et al. Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell 2013;12:167–179.
20. Nguyen PK, Nag D,WuJC. Methods to assess stem cell lineage, fate and function. Adv Drug Deliv Rev 2010;62:1175–1186.
21. Lee AS, Tang C, Cao F et al. Effects of cell number on teratoma formation by human embryonic stem cells. Cell Cycle 2009;8: 2608–2612.
22. Hong SG, Winkler T, Wu C et al. Path to the clinic: Assessment of iPSC-based cell therapies in vivo in a nonhuman primate model. Cell Rep 2014;7:1298–1309.
23. Alper J. Geron gets green light for human trial of ES cell-derived product. Nat Biotechnol 2009;27:213–214.
24. Frantz S. Embryonic stem cell pioneer Geron exits field, cuts losses. Nat Biotechnol 2012;30:12–13.
25. Sverdlov ED, Mineev K. Mutation rate in stem cells: An underestimated barrier on the way to therapy. Trends Mol Med 2013;19: 273–280.
26. Amps K, Andrews PW, Anyfantis G et al. Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol 2011;29:1132–1144.
27. Ben-David U, Benvenisty N. High prevalence of evolutionarily conserved and speciesspecific genomic aberrations in mouse pluripotent stem cells. STEM CELLS 2012;30:612–622.
28. Fazeli A, Liew CG, Matin MM et al. Altered patterns of differentiation in karyotypically abnormal human embryonic stem cells. Int J Dev Biol 2011;55:175–180.
29. Hovatta O, Jaconi M, Töhönen V et al. A teratocarcinoma-like human embryonic stem cell (hESC) line and four hESC lines reveal potentially oncogenic genomic changes. PLoS One 2010;5:e10263.
30. Lund RJ, Nikula T, Rahkonen N et al. Highthroughput karyotyping of human pluripotent stemcells. StemCellRes (Amst) 2012;9:192–195.
31. Mayshar Y, Ben-David U, Lavon N et al. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 2010;7:521–531.
32. Närvä E, Autio R, Rahkonen N et al. Highresolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity. Nat Biotechnol 2010;28:371–377.
33. Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer 2011;11: 268–277.
34. Ben-David U, Mayshar Y, Benvenisty N. Large-scale analysis reveals acquisition of lineage-specific chromosomal aberrations in human adult stem cells. Cell Stem Cell 2011;9: 97–102.
35. Hyka-Nouspikel N, Desmarais J, Gokhale PJ et al. Deficient DNA damage response and cell cycle checkpoints lead to accumulation of point mutations in human embryonic stem cells. STEM CELLS 2012;30:1901–1910.
36. Draper JS, Smith K, Gokhale P et al. Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells. Nat Biotechnol 2004;22:53–54.
37. Lee AS, Tang C, Rao MS et al. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat Med 2013;19:998–1004.
38. Sensebé L, Tarte K, Galipeau J et al. Limited acquisition of chromosomal aberrations in human adult mesenchymal stromal cells. Cell Stem Cell 2012;10:9–10; author reply 10–11.
39. Ben-David U, Mayshar Y, Benvenisty N. Significant acquisition of chromosomal aberrations in human adult mesenchymal stem cells: Response to Senseb´e et al. Cell Stem Cell 2012;10:10–11.
40. Gonz´alez F, Bou´e S, Izpis ´ua Belmonte JC. Methods for making induced pluripotent stem cells: Reprogramming `a la carte. Nat Rev Genet 2011;12:231–242.
41. Warren L, Manos PD, Ahfeldt T et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010; 7:618–630.
42. Kim D, Kim C-H, Moon J-I et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009;4:472–476.
43. Fusaki N, Ban H, Nishiyama A et al. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad, Ser B, Phys Biol Sci 2009;85:348–362.
44. Buganim Y, Markoulaki S, van Wietmarschen N et al. The developmental potential of iPSCs is greatly influenced by reprogramming factor selection. Cell Stem Cell 2014;15: 295–309.
45. Wu T, Liu Y, Wen D et al. Histone variant H2A.X deposition pattern serves as a functional epigenetic mark for distinguishing the developmental potentials of iPSCs. Cell Stem Cell 2014; 15:281–294.
46. Miyoshi N, Ishii H, Nagano H et al. Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell 2011;8:633–638.
47. Hou P, Li Y, Zhang X et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 2013; 341:651–654.
48. González F, Georgieva D, Vanoli F et al. Homologous recombination DNA repair genes play a critical role in reprogramming to a pluripotent state. Cell Reports 2013;3:651–660.
49. Su R-J, Yang Y, Neises A et al. Few single nucleotide variations in exomes of human cord blood induced pluripotent stem cells. PLoS One 2013;8:e59908.
50. Le Blanc K, Tammik L, Sundberg B et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003; 57:11–20.
51. Le Blanc K, Tammik C, Rosendahl K et al. HLA expression and immunologic properties of differentiatedandundifferentiatedmesenchymal stem cells. Exp Hematol 2003;31:890–896.
52. Aggarwal S, PittengerMF. Humanmesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815–1822.
53. Bartholomew A, Sturgeon C, Siatskas M et al. Mesenchymal stemcells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002;30:42–48.
54. Majumdar MK, Keane-Moore M, Buyaner D et al. Characterization and functionality of cell surfacemolecules on humanmesenchymal stem cells. J Biomed Sci 2003;10:228–241.
55. Tse WT, Pendleton JD, Beyer WM et al. Suppressionof allogeneic T-cell proliferation byhuman marrow stromal cells: Implications in transplantation. Transplantation 2003;75:389–397.
56. Jaiswal S, Jamieson CH, Pang WW et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009;138:271–285.
57. Zheng J, Umikawa M, Zhang S et al. Ex vivo expanded hematopoietic stem cells overcome the MHC barrier in allogeneic transplantation. Cell Stem Cell 2011;9:119–130.
58. Locatelli F, Lucarelli B, Merli P. Current and future approaches to treat graft failure after allogeneic hematopoietic stem cell transplantation. Expert Opin Pharmacother 2014; 15:23–36.
59. Pasquini MC, Wang Z, Horowitz MM et al. 2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): Current uses and outcomes of hematopoietic cell transplants forbloodandbonemarrow disorders. Clin Transpl 2010;2010:87–105.
60. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 2012;12:443–458.
61. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymalstem cells. Lancet 2004;363:1439–1441.
62. Le Blanc K, Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of steroidresistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008;371: 1579–1586.
63. Kim EJ, Kim N, Cho SG. The potentialuse of mesenchymal stem cells in hematopoietic stem cell transplantation. Exp Mol Med 2013;45:e2.
64. Draper JS, Pigott C, Thomson JA et al. Surface antigens of human embryonic stem cells: Changes upon differentiation in culture. J Anat 2002;200:249–258.
65. Tachibana M, Amato P, SparmanMet al. Human embryonic stem cells derived by somatic cell nuclear transfer. Cell 2013;153: 1228–1238.
66. Chung YG, Eum JH, Lee JE et al.Humansomatic cell nuclear transfer using adult cells. Cell Stem Cell 2014;14:777–780.
67. Zhao T, Zhang ZN, Rong Z et al. Immunogenicity of induced pluripotent stem cells. Nature 2011;474:212–215.
68. Guha P, Morgan JW, Mostoslavsky G et al. Lack of immuneresponse to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell 2013;12:407–412.
69. Araki R, Uda M, Hoki Y et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 2013;494:100–104.
70. de Almeida PE, Meyer EH, Kooreman NG et al. Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance. Nat Commun 2014;5:3903.
71. Morizane A, Doi D, Kikuchi T et al. Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate. Stem Cell Reports 2013;1:283–292.
72. Taylor CJ, Bolton EM, Pocock S et al. Banking on human embryonic stem cells: Estimating the number of donor cell lines needed for HLA matching. Lancet 2005;366:2019–2025.
73. Taylor CJ, Peacock S, Chaudhry AN et al. Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types. Cell Stem Cell 2012; 11:147–152.
74. Nakatsuji N, Nakajima F, Tokunaga K. HLA-haplotype banking and iPS cells. Nat Biotechnol 2008;26:739–740.
75. Zhang W, Zhao S, Rao W et al. A novel core-shell microcapsule for encapsulation and 3D culture of embryonic stem cells. J Mater Chem B Mater BiolMed 2013;2013:1002–1009.
76. Salick M, Boyer R, Koonce C et al. Differentiation of human embryonic stem cells encapsulated in hydrogel matrix materialsExperimental and AppliedMechanics. In: Proulx T, edNew York, NY: Springer, 2011415–421.
77. Tuch BE, Hughes TC, Evans MDM. Encapsulated pancreatic progenitors derived from human embryonic stem cells as a therapy for insulin-dependent diabetes. Diabetes Metab Res Rev 2011;27:928–932.
78. Schulz TC, Young HY, Agulnick AD et al. A scalable system for production of functional pancreatic progenitors from human embryonic stem cells. PLoS One 2012;7:e37004.
79. Lee SH, Hao E, Savinov AY et al. Human beta-cell precursors mature into functional insulin-producing cells in an immunoisolation device: Implications for diabetes cell therapies. Transplantation 2009;87:983–991.
80. Kirk K, Hao E, Lahmy R et al. Human embryonic stem cell derived islet progenitors mature inside an encapsulation device without evidence of increased biomass or cell escape. Stem Cell Res (Amst) 2014;12:807–814.
81. Freimark D, Pino-Grace P, Pohl S et al. Use of encapsulated stem cells to overcome the bottleneck of cell availability for cell therapy approaches. Transfus Med Hemother 2010;37: 66–73.
82. Horwitz EM, Gordon PL, Koo WK et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA 2002;99:8932–8937.
83. Martin MJ, Muotri A, Gage F et al. Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat Med 2005;11: 228–232.
84. Jung JW, Kwon M, Choi JC et al. Familial occurrence of pulmonary embolism after intravenous, adipose tissue-derived stem cell therapy. Yonsei Med J 2013;54:1293–1296.
85. Syková E, Jendelová P, Urdzíková L et al. Bone marrow stem cells and polymer hydrogels: Two strategies for spinal cord injury repair. Cell Mol Neurobiol 2006;26:1113–1129.
86. Walczak P, Zhang J, Gilad AA et al. Dualmodality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia. Stroke 2008;39:1569–1574.
87. Bacou F, el Andalousi RB, Daussin PA et al. Transplantation of adipose tissuederived stromal cells increases mass and functional capacity of damaged skeletal muscle. Cell Transplant 2004;13:103–111.
88. Moscoso I, Barallobre J, de Ilarduya OM et al. Analysis of different routes of administration of heterologous 5-azacytidine-treated mesenchymal stem cells in a porcine model of myocardial infarction. Transplant Proc 2009; 41:2273–2275.
89. Li L, Jiang Q, DingGet al. Effects of administration route on migration and distribution of neural progenitor cells transplanted into rats with focal cerebral ischemia, an MRI study. J Cereb Blood Flow Metab 2010;30:653–662.
90. Zvibel I, Smets F, Soriano H. Anoikis: Roadblock to cell transplantation? Cell Transplant 2002;11:621–630.
91. Steward O, Sharp KG, Matsudaira Yee K. Long-distance migration and colonization of transplanted neural stem cells. Cell 2014;156: 385–387.
92. Goldring CE, Duffy PA, Benvenisty N et al. Assessing the safety of stem cell therapeutics. Cell Stem Cell 2011;8:618–628.
93. Hyun I, Lindvall O, Ährlund-Richter L et al. New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell 2008;3:607–609.
94. Halme DG, Kessler DA. FDA regulation of stem-cell-based therapies. N Engl J Med 2006; 355:1730–1735.
95. Dobkin BH, Curt A, Guest J. Cellular transplants in China: Observational study from the largest human experiment in chronic spinal cord injury. Neurorehabil Neural Repair 2006; 20:5–13.
96. Zarzeczny A, Caulfield T, Ogbogu U et al. Professional regulation: A potentially valuable tool in responding to “stem cell tourism.” Stem Cell Reports 2014;3:379–384.
97. Cyranoski D. Stem cells in Texas: Cowboy culture. Nature 2013;494:166–168.
98. Cyranoski D. FDA’s claims over stem cells upheld. Nature 2012;488:14.
99. Nature News. Biomedical briefing. Nat Med 2014;20:226–227.
100. Kuroda T, Yasuda S, Kusakawa S et al. Highly sensitive in vitro methods for detection of residual undifferentiated cells in retinal pigment epithelial cells derived from human iPS cells. PLoS One 2012;7:e37342.
101. Lawrenz B, Schiller H, Willbold E et al. Highly sensitive biosafety model for stem-cellderived grafts. Cytotherapy 2004;6:212–222.
102. MacIsaac ZM, Shang H, Agrawal H et al. Long-termin-vivotumorigenic assessmentofhuman culture-expanded adipose stromal/stem cells. Exp Cell Res 2012;318:416–423.
103. Kanemura H, Go MJ, Shikamura M et al. Tumorigenicity studies of induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium(RPE) for the treatment of age-relatedmacular degeneration. PLoS One 2014;9:e85336.
104. Zhang YS, Wang Y, Wang L et al. Labeling human mesenchymal stem cells with gold nanocages for in vitro and in vivo tracking by two-photon microscopy and photoacoustic microscopy. Theranostics 2013;3:532–543.
105. Cunningham JJ, Ulbright TM, Pera MF et al. Lessons from human teratomas to guide development of safe stem cell therapies. Nat Biotechnol 2012;30:849–857.
106. Abe Y, Oshika Y, Ohnishi Y et al. A xenograft line of human teratocarcinoma established by serial transplantation in severe combined immunodeficient (SCID) mice. APMIS 1997;105:283–289.
107. Sharpe ME, Morton D, Rossi A. Nonclinical safety strategies for stem cell therapies. Toxicol Appl Pharmacol 2012;262:223–231.
108. Reisner Y, Dagan S. The Trimera mouse: Generating human monoclonal antibodies and an animal model for human diseases. Trends Biotechnol 1998;16:242–246.
109. Macchiarini F, Manz MG, Palucka AK et al. Humanized mice: Are we there yet? J Exp Med 2005;202:1307–1311.
110. Rodriguez-Porcel M, Wu JC, Gambhir SS. Molecular imaging of stem cells. Cambridge, MA: StemBook, 2008.
111. Kuchmiy AA, Efimov GA, Nedospasov SA. Methods for in vivo molecular imaging. Biochemistry (Mosc) 2012;77:1339–1353.
112. Kraitchman DL, Bulte JW. In vivo imaging of stem cells and Beta cells using direct cell labeling and reporter gene methods. Arterioscler Thromb Vasc Biol 2009;29:1025–1030.
113. Kraitchman DL, Tatsumi M, Gilson WD et al. Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. Circulation 2005;112:1451–1461.
114. Brenner W, Aicher A, Eckey T et al. 111InlabeledCD34+ hematopoietic progenitor cells in a rat myocardial infarction model. J Nucl Med 2004;45:512–518.
115. Kang WJ, Kang HJ, Kim HS et al. Tissue distribution of 18F-FDG-labeled peripheral hematopoietic stem cells after intracoronary administration in patients with myocardial infarction. J Nuclear Med 2006;47:1295–1301.
116. McColgan P, Sharma P, Bentley P. Stem cell tracking in human trials: A meta-regression. Stem Cell Rev 2011;7:1031–1040.
117. Zhu J, Zhou L, XingWu F. Tracking neural stem cells in patients with brain trauma. NEngl J Med 2006;355:2376–2378.
118. Zhang WY, Ebert AD, Narula J et al. Imaging cardiac stem cell therapy: Translations to human clinical studies. J Cardiovasc Transl Res 2011;4:514–522.
119. de Vries IJM, Lesterhuis WJ, Barentsz JO et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 2005;23: 1407–1413.
120. Ahrens ET, Zhong J. In vivoMRI cell tracking using perfluorocarbon probes and fluorine- 19 detection. NMR Biomed 2013;26:860–871.
121. Partlow KC, Chen J, Brant JA et al. 19F magnetic resonance imaging for stem/ progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. FASEB J 2007;21: 1647–1654.
122. Boehm-Sturm P, Mengler L, Wecker S et al. In vivo tracking of human neural stem cells with 19F magnetic resonance imaging. PLoS One 2011;6:e29040.
123. Bible E, Dell’Acqua F, Solanky B et al. Non-invasive imaging of transplanted human neural stem cells and ECM scaffold remodeling in the stroke-damaged rat brain by (19)F- and diffusion- MRI. Biomaterials 2012;33:2858–2871.
124. Ruiz-Cabello J, Barnett BP, Bottomley PA et al. Fluorine (19F) MRSand MRI in biomedicine. NMR Biomed 2011;24:114–129.
125. Ahrens ET, Helfer BM, O’Hanlon CF et al. Clinical cell therapy imaging using a perfluorocarbon tracer and fluorine-19 MRI. Magn Reson Med 2014;72:1696–1701.
126. Gu E, Chen WY, Gu J et al. Molecular imaging of stem cells: Tracking survival, biodistribution, tumorigenicity, and immunogenicity. Theranostics 2012;2:335–345.
127. Gilad AA, McMahon MT, Walczak P et al. Artificial reporter gene providing MRI contrast based on proton exchange. Nat Biotechnol 2007;25:217–219.
128. Wu JC, Spin JM, Cao F et al. Transcriptional profiling of reporter genes used for molecular imaging of embryonic stem cell transplantation. Physiol Genomics 2006;25: 29–38.
129. Gyöngyösi M, Blanco J, Marian T et al. Serial noninvasive in vivo positron emission tomographic tracking of percutaneously intramyocardially injected autologous porcine mesenchymal stem cells modified for transgene reporter gene expression. Circ Cardiovasc Imaging 2008;1:94–103.
130. Pei Z, Lan X, Cheng Z et al. Multimodality molecular imaging tomonitor transplanted stem cells for the treatment of ischemic heart disease. PLoS One 2014;9:e90543.
131. Ray P, De A. Reportergeneimagingin therapy and diagnosis. Theranostics 2012;2:333–334.
132. Yaghoubi SS, Campbell DO, Radu CG et al. Positron emission tomography reporter genes and reporter probes: Gene and cell therapy applications. Theranostics 2012;2:374–391.
133. Yaghoubi SS, Couto MA, Chen CC et al. Preclinical safety evaluation of 18F-FHBG: A PET reporter probe for imaging herpes simplex virus type 1 thymidine kinase (HSV1-tk) or mutant HSV1-sr39tk’s expression. J Nuclear Med 2006;47:706–715.
134. Yaghoubi SS, Gambhir SS. PET imaging of herpes simplex virus type 1 thymidine kinase (HSV1-tk) or mutant HSV1-sr39tk reporter gene expression in mice and humans using [18F] FHBG. Nat Protoc 2006;1:3069–3075.
135. Wang LV, Hu S. Photoacoustic tomography: In vivo imaging from organelles to organs. Science 2012;335:1458–1462.
136. Yao J, Wang LV. Photoacoustic tomography: Fundamentals, advances and prospects. Contrast Media Mol Imaging 2011;6:332–345.
137. Dokos C, Masjosthusmann K, Rellensmann G et al. Fatal human metapneumovirus infection following allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2013;15:E97–E101.
138. Lòpez MM, Valenzuela JE, Álvarez FC et al. Long-term problems related to immunosuppression. Transpl Immunol 2006;17:31–35.
139. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplantrecipients. Recommendations and Reports: Morbidity andMortalityWeekly Report, Vol. 49. Washington, D.C.: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Epidemiology Program, 2001.
140. Hurley CK, Raffoux C. WorldMarrow Donor Association: International standards for unrelated hematopoietic stem cell donor registries. Bone Marrow Transplant 2004;34:103–110.
141. Kallianpur AR. Genomic screening and complications of hematopoietic stem cell transplantation: Has the time come? Bone Marrow Transplant 2005;35:1–16.
142. Berro M, Mayor NP, Maldonado-Torres H et al. Association of functional polymorphisms of the transforming growth factor B1 gene with survival and graft-versus-host disease after unrelateddonor hematopoietic stemcell transplantation. Haematologica 2010;95:276–283.
143. Viel DO, Tsuneto LT, Sossai CR et al. IL2 and TNFA gene polymorphisms and the risk of graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Scand J Immunol 2007;66:703–710.
144. Tate CC, Shear DA, Tate MC et al. Laminin and fibronectin scaffolds enhance neural stem cell transplantation into the injured brain. J Tissue Eng Regen Med 2009;3:208–217.
145. Guan J, Zhu Z, Zhao RC et al. Transplantation of human mesenchymal stem cells loaded on collagen scaffolds for the treatment of traumatic brain injury in rats. Biomaterials 2013;34:5937–5946.
146. Guyette JP, Gilpin SE, Charest JM et al. Perfusion decellularization of whole organs. Nat Protoc 2014;9:1451–1468.
147. Zhou Q, Li L, Li J. Stem cells with decellularized liver scaffolds in liver regeneration and their potential clinical applications. Liver Int 2014;35:687–694.
148. Sabetkish S, Kajbafzadeh AM, Sabetkish N et al. Whole-organ tissue engineering: Decellularization and recellularization of three-dimensional matrix liver scaffolds. J Biomed Mater Res A 2014 (in press).
149. Bonandrini B, Figliuzzi M, Papadimou E et al. Recellularization of well-preserved acellular kidney scaffold using embryonic stem cells. Tissue Eng Part A 2014;20:1486–1498.
150. Badylak SF, Freytes DO, Gilbert TW. Extracellular matrix as a biological scaffold material: Structure and function. Acta Biomater 2009;5:1–13.
151. Fishman JM, Lowdell MW, Urbani L et al. Immunomodulatory effect of a decellularized skeletal muscle scaffold in a discordant xenotransplantation model. Proc Natl Acad Sci USA 2013;110:14360–14365.
152. Crapo PM, Gilbert TW, Badylak SF. An overview of tissue and whole organ decellularization processes. Biomaterials2011;32:3233–3243.
153. Song JJ, Ott HC. Organ engineering based on decellularized matrix scaffolds. Trends Mol Med 2011;17:424–432.
154. Daly KA, Liu S, Agrawal V et al. Damage associated molecular patterns within xenogeneic biologic scaffolds and their effects on host remodeling. Biomaterials 2012;33:91–101.
155. Valentin JE, Badylak JS, McCabe GP et al. Extracellularmatrix bioscaffolds for orthopaedic applications. A comparative histologic study. J Bone Joint Surg Am 2006;88:2673–2686.
156. Gunatillake PA, Adhikari R. Biodegradable synthetic polymers for tissue engineering. Eur Cell Mater 2003;5:1–16; discussion 16.
157. Willerth SM, Sakiyama-Elbert SE. Combining stem cells and biomaterial scaffolds for constructing tissues and cell delivery. Cambridge, MA: StemBook, 2008.
158. Demirbag B, Huri PY, Kose GT et al. Advanced cell therapies with and without scaffolds. Biotechnol J 2011;6:1437–1453.
159. Ben-David U, Mayshar Y, Benvenisty N. Virtual karyotyping of pluripotent stem cells on the basis of their global gene expression profiles. Nat Protoc 2013;8:989–997.
160. Hay DC, Pernagallo S, Diaz-Mochon JJ et al. Unbiased screening of polymer libraries to define novel substrates for functional hepatocytes with inducible drug metabolism. Stem Cell Res (Amst) 2011;6:92–102.
161. Desmarais JA, Hoffmann MJ, Bingham G et al. Human embryonic stem cells fail to activate CHK1 and commit to apoptosis in response to DNA replication stress. STEM CELLS 2012;30:1385–1393.
162. Tang C, Lee AS, Volkmer JP et al. An antibody against SSEA-5 glycan on humanpluripotent stem cells enables removal of teratoma-forming cells. Nat Biotechnol 2011;29:829–834.
163. Ben-David U, Nudel N, Benvenisty N. Immunologic and chemical targeting of the tight-junction protein Claudin-6 eliminates tumorigenic human pluripotent stem cells. Nat Commun 2013;4:1992.
164. Benevento M, Munoz J. Role of mass spectrometry-based proteomics in the study of cellular reprogramming and induced pluripotent stem cells. Expert Rev Proteomics 2012;9: 379–399.
165. Reiland S, Salekdeh GH, Krijgsveld J. Defining pluripotent stem cells through quantitative proteomic analysis. Expert Rev Proteomics 2011;8:29–42.
166. Sinden JD, Muir KW. Stem cells in stroke treatment: The promise and the challenges. Int J Stroke 2012;7:426–434.
167. James ML, Gambhir SS. A molecular imaging primer: Modalities, imaging agents, and applications. Physiol Rev 2012;92: 897–965.
168. de Almeida PE, van Rappard JR, Wu JC. In vivo bioluminescence for tracking cell fate and function. Am J Physiol Heart Circ Physiol 2011;301:H663–H671.
169. Welling MM, Duijvestein M, Signore A et al. In vivo biodistribution of stem cells using molecular nuclear medicine imaging. J Cell Physiol 2011;226:1444–1452.
170. Cromer Berman SM, Walczak P, Bulte JW. Tracking stem cells using magnetic nanoparticles. Wiley Interdiscip Rev NanomedNanobiotechnol 2011;3:343–355.
171. Rosen AB, Kelly DJ, Schuldt AJT et al. Finding fluorescent needles in the cardiac haystack: Tracking human mesenchymal stem cells labeled with quantum dots for quantitative in vivo three-dimensional fluorescence analysis. STEM CELLS 2007;25:2128–2138.
172. Lin S, Xie X, Patel MR et al. Quantum dot imaging for embryonic stem cells. BMCBiotechnol 2007;7:67.
173. Eisenblätter M, Ehrchen J, Varga G et al. In vivo optical imaging of cellular inflammatory response in granuloma formation using fluorescence-labeled macrophages. J Nucl Med 2009;50:1676–1682.
174. Zinn KR, Chaudhuri TR, Szafran AA et al. Noninvasive bioluminescence imaging in small animals. ILAR J 2008;49:103–115.
175. Eghtedari M, Oraevsky A, Copland JA et al. High sensitivity of in vivo detection of gold nanorods using a laser optoacoustic imaging system. Nano Lett 2007;7:1914–1918.
176. Chamberland DL, Agarwal A, Kotov N et al. Photoacoustic tomography of joints aided by an Etanercept-conjugated gold nanoparticle contrast agent: An ex vivo preliminary rat study. Nanotechnology 2008;19: 095101.